Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Earn-Out Shares (non-vested) Earn Out Shares Nonvested [Member] Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must "earn" part of the purchase price based on the performance of the business. RSL 2021 EIP Roivant Sciences Ltd2021 Equity Incentive Plan [Member] The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the "RSL 2021 EIP"). Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Share-Based Payment Arrangement, Sixth And Final Tranche Share-Based Payment Arrangement, Sixth And Final Tranche [Member] Share-Based Payment Arrangement, Sixth And Final Tranche Adjustment to Compensation, Amount Adjustment to Compensation Amount Common shares aggregate offering price authorized Common Shares Offering Price Authorized The common shares aggregate offering price authorized to issue under equity offering program. Financial Instrument [Axis] Financial Instrument [Axis] Number of RSUs and PSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Segment Reporting [Abstract] Segment Reporting [Abstract] Income tax payable, noncurrent Taxes Payable, Noncurrent Taxes Payable, Noncurrent Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 722,668,062 and 720,352,386 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively Common Stock, Value, Issued Compensation-related expenses Employee-related Liabilities, Current Restatement Determination Date Restatement Determination Date Accrued compensation-related expenses Employee-related Liabilities Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cost of revenues Operating Costs The total amount of operating cost and expense. Cash, Cash Equivalents, and Marketable Securities [Line Items] Marketable Securities [Line Items] U.S. Treasury securities, available-for-sale, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated accrual contractual costs Accumulated Contractual Costs Accumulated Contractual Costs RSL RSL [Member] RSL Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Schedule of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross U.S. Treasury securities US Treasury Securities, Available-for-Sale [Member] US Treasury Securities, Available-for-Sale Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Assets: Assets, Fair Value Disclosure [Abstract] Cash and Cash Equivalents [Abstract] Non-vested balance, beginning (in shares) Non-vested balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share Repurchase Program [Domain] Share Repurchase Program [Domain] Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Datavant Datavant [Member] Datavant Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Taxes payable related to net settlement of equity awards Taxes Payable Related To Net Settlement Of Equity Awards Taxes Payable Related To Net Settlement Of Equity Awards U.S. Treasury securities, available-for-sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Entity Address, City or Town Entity Address, City or Town Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation and Other Compensation Plans [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Class of Stock [Axis] Class of Stock [Axis] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Proceeds from issuance of the Company’s common shares under employee stock purchase plan Proceeds from Stock Plans Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Total other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Term of trailing trading days, weighted average price use to calculate performance condition of PSUs Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition of PSUs Period of trailing trading days, weighted average trading price used to calculate performance Condition of PSUs in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Subsequent Event Type [Axis] Subsequent Event Type [Axis] Litigation settlement receivable Litigation Settlements Receivable, Current Litigation Settlements Receivable, Current Genevant Sciences GmbH Genevant Sciences GmbH [Member] Genevant Sciences GmbH Significant Accounting Policies /Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Significant Segment Expenses Segment Reporting [Table Text Block] Noncontrolling Interests Noncontrolling Interest [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Schedule of Changes in Fair Value of the Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Taxes paid related to net settlement of equity awards Payments Of Taxes For The Repurchase Of Equity Payments of Taxes for the Repurchase of Equity. Due after one year but within five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Income tax payable Increase (Decrease) in Income Taxes Payable Document Period End Date Document Period End Date Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Forfeited/Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Cowen Cowen And Company LLC [Member] An affiliate with whom the entity entered into a sales agreement. Shareholders' Equity Equity [Text Block] Other Noncash Other Amount of expense or loss included in net income that result in no cash flow, classified as other. Security Exchange Name Security Exchange Name Liabilities at fair value Liabilities, Fair Value Disclosure Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Cash and cash equivalents Cash and Cash Equivalent [Abstract] Changes in fair value of liability instruments, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Operating lease liabilities Operating Lease, Liability, Current Segment Reporting Segment Reporting, Policy [Policy Text Block] Cash contributions to majority-owned subsidiaries Proceeds From Cash Contributions To Majority-Owned Subsidiaries Proceeds From Cash Contributions To Majority-Owned Subsidiaries Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Number of vesting tranches Number of Vesting Tranches Number of Vesting Tranches Marketable Securities [Table] Marketable Securities [Table] Net Loss per Common Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Purchase obligation, to be paid, year one Purchase Obligation, to be Paid, Year One PSUs performance condition satisfied (in shares) PSUs Performance Condition Satisfied, Shares PSUs Performance Condition Satisfied, Shares Total liabilities Liabilities Entity Trading Symbol Trading Symbol Discount rate Measurement Input, Discount Rate [Member] Debt securities, available-for-sale U.S. Treasury securities, available-for-sale, Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Purchases Payments to Acquire Debt Securities, Available-for-Sale Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Asset Class [Domain] Asset Class [Domain] Litigation settlement receivable Increase (Decrease) In Litigation Settlement Receivables Increase (Decrease) In Litigation Settlement Receivables Schedule of Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalent, and Investment [Table Text Block] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent U.S. Treasury securities US Treasury Securities [Member] Dividends payable Dividends Payable Money market funds Cash Equivalent, Money Market Fund, Carrying Value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares) Stock Issued During Period, Shares, In Connection With Equity Incentive Plans And Tax Withholding Payments The number of shares issued in connection with equity incentive plans and tax withholding payments. Litigation settlement, fixed payment receivable Litigation Settlements, Fixed Payment Receivable Litigation Settlements, Fixed Payment Receivable Other assets Increase (Decrease) in Other Noncurrent Assets Reportable Segment Reportable Segment [Member] Reportable Segment Other general and administrative expenses Other General and Administrative Expense Schedule of Changes in Fair Value of the Level 3 Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash (included in “Other current assets”) Restricted Cash, Current Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent PSUs satisfied performance condition, shares (in shares) PSUs Satisfied Performance Condition, Shares PSUs Satisfied Performance Condition, Shares Income (loss) from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest All Executive Categories All Executive Categories [Member] Repurchase of the Company’s common shares Stock Repurchased and Retired During Period, Value Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Vesting [Domain] Vesting [Domain] Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset PSUs holding period before common shares may be sold by executive PSUs Holding Period Before Common Shares May be Sold by Executive PSUs Holding Period Before Common Shares May be Sold by Executive Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Personnel-related expenses Personnel Related Expenses Personnel Related Expenses Segment Information Segment Reporting [Text Block] Proceeds from maturities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Recent Transactions and Developments Recent Transactions And Developments Text Block [Text Block] The entire disclosure for recent transactions and development. Expiration Date Trading Arrangement Expiration Date Investments measured at fair value Aggregate fair value investment Investment Investments, Fair Value Disclosure Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Location, Statement of Income, Balance [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Ownership of shares, percentage Ownership Of Shares, Percentage The percentage ownership of a subsidiary. Total shareholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Fair Value Measurements [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operations [Line Items] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Activity for Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Segment Information [Line Items] Segment Reporting [Line Items] Common stock repurchase authorized amount Share Repurchase Program, Authorized, Amount Document Quarterly Report Document Quarterly Report Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Litigation settlement, fixed payment, percentage Litigation Settlement, Fixed Payment, Percentage Litigation Settlement, Fixed Payment, Percentage Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Schedule of Unrealized Positions for Marketable Securities Marketable Securities [Table Text Block] Litigation settlement, contingent payment receivable Litigation Settlement, Contingent Payment Receivable Litigation Settlement, Contingent Payment Receivable Available-for-Sale Marketable Securities Available-for-Sale Marketable Securities In Unrealized Loss Position [Member] Available-for-Sale Marketable Securities In Unrealized Loss Position Share repurchase program, increased authorized, amount Share Repurchase Program, Increased Authorized, Amount Share Repurchase Program, Increased Authorized, Amount Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Change in fair value of liability instruments Change in fair value of liability instruments Gain (Loss) On Fair Value Of Liability Instruments Amount of gain (loss) on fair value of liability instruments. Equity Component [Domain] Equity Component [Domain] Subsidiary Equity Incentive Plans Subsidiary Equity Incentive Plans [Member] Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Change in fair value of investment in Datavant, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Adoption Date Trading Arrangement Adoption Date Counterparty Name [Domain] Counterparty Name [Domain] Shareholders’ equity attributable to Roivant Sciences Ltd. Equity, Attributable to Parent Assets Assets [Abstract] Restricted stock units and performance restricted stock units (non-vested) Restricted Stock And Performance Stock Units [Member] Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target. Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Gain on litigation settlement Gain on litigation settlement Litigation Settlement, Gain Insider Trading Policies and Procedures [Line Items] Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Anti-FcRn franchise—other clinical and nonclinical Anti Fc Rn Franchise Other Clinical And Nonclinical [Member] Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other clinical and nonclinical Number of PSUs Performance Shares [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Certain Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Recent Transactions and Developments [Abstract] Recent Transactions and Developments [Abstract] Recent Transactions and Developments [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Schedule of Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net (Loss) Income per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key All Adjustments to Compensation All Adjustments to Compensation [Member] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Accretion of discount and amortization of premium on held-to-maturity marketable securities, net Accretion (Amortization) of Discounts and Premiums, Held-to-Maturity Marketable Securities Accretion (Amortization) of Discounts and Premiums, Held-to-Maturity Marketable Securities Income Statement [Abstract] Income Statement [Abstract] Shareholders’ equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Ownership [Axis] Ownership [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Change in fair value of investments Change in fair value of investments Gain (Loss) on Investments Investment, Name [Axis] Investment, Name [Axis] Number of marketable securities Number Of Debt Securities, Available-for-Sale Number Of Debt Securities, Available-for-Sale Marketable securities, available-for-sale Marketable Securities, Available-for-Sale [Abstract] Marketable Securities, Available-for-Sale Operating expenses: Less: Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] City Area Code City Area Code Number of RSUs Restricted Stock [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Subsequent Events Subsequent Events [Text Block] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Volatility Measurement Input, Price Volatility [Member] Name Forgone Recovery, Individual Name Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Balance Sheet Related Disclosures [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets Entity [Domain] Entity [Domain] Research and Development, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Other stock based awards and instruments issued Other Stock Based Awards And Instruments Issued [Member] The other stock based awards and instruments issued related to the awards consisting of stock units. U.S. Treasury securities, available-for-sale, Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Share-Based Compensation Share-Based Payment Arrangement [Text Block] Issuance of the Company’s common shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Fair Value Measurements [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Share-based compensation expense Share-Based Payment Arrangement, Expense Repurchase of the Company's common shares (in shares) Stock Repurchased and Retired During Period, Shares Marketable securities Marketable Securities, Current Other liabilities Other Liabilities, Noncurrent Brepocitinib Brepocitinib [Member] Brepocitinib it represent selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Fair Value Measurements [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Income tax payable Taxes Payable, Current Total operating expenses Operating Expenses Money market funds Money Market Funds [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Schedule of Fair Value Calculation Using Significant Unobservable Inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized (losses) gains on available-for-sale securities Unrealized (losses) gains on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Number of shares acquired (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate bonds Corporate Debt Securities [Member] Net loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash used in financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Investment in equity securities, measurement input Fair Value Asset, Measurement Input Fair value asset, measurement input. Country Region Country Region Unrealized gains (losses) on investments Unrealized Gain (Loss) on Investments Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Moderna Moderna [Member] Moderna Ownership [Domain] Ownership [Domain] Research and development (includes $8,721 and $11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) Research and development expenses Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Issuance of subsidiary shares to the Company and cash contributions to majority-owned subsidiaries Issuance Of Subsidiary Common Shares To The Company And Capital Contributions To Subsidiaries Issuance Of Subsidiary Common Shares To The Company And Capital Contributions To Subsidiaries March 2020 CVARs March 2020 Capped Value Appreciation Rights Grants [Member] Grant date of Capped Value Appreciation Rights (CVARs). Accretion of discount and amortization of premium on available-for-sale marketable securities, net Accretion (Amortization) of Discounts and Premiums, Available-for-Sale Marketable Securities Accretion (Amortization) of Discounts and Premiums, Available-for-Sale Marketable Securities Anti-FcRn franchise—rheumatology diseases Anti Fc Rn Franchise Rheumatology Diseases [Member] Rheumatology diseases is a chronic progressive autoimmune disease that causes inflammation in the joints and surrounding tissues. Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Financial Instruments [Domain] Financial Instruments [Domain] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Tax [Abstract] Stock purchases Stock Repurchased During Period, Value Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Cash Cash Anti-FcRn franchise—dermatology diseases Anti Fc Rn Franchise Dermatology Diseases [Member] Dermatology diseases is a rare, chronic skin disease characterized by skin-specific disease activity, inflammation and eventually damage. Segment Reporting [Table] Segment Reporting [Table] Common shares available for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Equity Method Investment [Table] Equity Method Investment [Table] Sale of Stock [Axis] Sale of Stock [Axis] Marketable Securities Marketable Securities, Policy [Policy Text Block] Other current assets Other Assets, Current Investment in Arbutus common shares Arbutus Biopharma Corporation [Member] The name of related party. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Number of shares repurchased (in shares) Stock Repurchased During Period, Shares Description of Business and Liquidity [Abstract] Description of Business and Liquidity [Abstract] Description of Business and Liquidity [Abstract] Exercise and vesting of subsidiary share awards Exercise And Vesting Of Subsidiary Share Based Awards The amount recognized in equity in the period due to the exercise and vesting of subsidiary share-based awards. Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Marketable Securities as Level 2 Measurements Within the Fair Value Hierarchy Investments Classified by Contractual Maturity Date [Table Text Block] Corporate bonds Corporate Bond Securities [Member] Schedule of Activity for Stock Option Share-Based Payment Arrangement, Option, Activity [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Net (Loss) Income per Common Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-FcRn franchise—endocrine diseases Anti Fc Rn Franchise Endocrine Diseases [Member] Endocrine disease is an autoimmune disease that affects the thyroid gland. Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Description of Business and Liquidity Business Description and Basis of Presentation [Text Block] Equity Components [Axis] Equity Components [Axis] Product and Service [Domain] Product and Service [Domain] Shareholders' Equity [Line Items] Class of Stock [Line Items] Entity Interactive Data Current Entity Interactive Data Current Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Stock Repurchase Program Stock Repurchase Program [Member] A program to buyback its own share. Comprehensive loss attributable to Roivant Sciences Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable, Trade Subsequent Events [Abstract] Subsequent Events [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other current liabilities Other Liabilities, Current Other assets Other Assets, Noncurrent Document Type Document Type Fair Value Measurements [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accrued expenses Total accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Investment in Datavant Class A units Datavant Holdings Inc [Member] The name of related party. Litigation settlement, amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Share repurchase program, remaining authorized, amount Share Repurchase Program, Remaining Authorized, Amount At-the-Market Equity Offering Program Equity Offerings At The Market [Member] Offering of "at-the-market" shares as per equity distribution agreement. Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Arrangement Duration Trading Arrangement Duration Subsequent Events [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Senior Executive Compensation Program Senior Executive Compensation Program [Member] Senior Executive Compensation Program Schedule of Activity for Performance Stock Units Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 10) Commitments and Contingencies Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Total estimated fair value of available-for-sale securities Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Schedule of Assets and Liabilities are Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Marketable securities Marketable Securities [Abstract] Award Type [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Closing price of common stock (in dollars per share) Share Price PEO Name PEO Name Accrued expenses Increase (Decrease) in Accrued Liabilities Cash, cash equivalents, and marketable securities Total cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-Term Investments Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Legal Entity [Axis] Legal Entity [Axis] Share price (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Share Price at Tranche Performance Period Share Based Compensation Arrangement by Share Based Payment Award, Share Price at Tranche Performance Period Cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Other expenses Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Eric Venker [Member] Eric Venker Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Stock options and performance stock options Stock Options And Performance Stock Options [Member] Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Common shares aggregate offering price authorized, remaining capacity available Common Shares Aggregate Offering Price Authorized Remaining Capacity Available The common shares aggregate offering price authorized remaining capacity to issue under equity offering program. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Subsequent Event [Table] Subsequent Event [Table] Equity method investment ownership percentage Equity Method Investment, Ownership Percentage Share-based compensation Share-Based Payment Arrangement, Noncash Expense Change in fair value of debt and liability instruments Gain (Loss) on Fair Value of Debt and Liability Instruments Amount of gain (loss) on fair value of debt and liability instruments. Anti-FcRn franchise—neurological diseases Anti Fc Rn Franchise Neurological Diseases [Member] Neurological disorders represent a complex array of medical conditions that fundamentally disrupt the functioning of the nervous system. These disorders affect the brain, spinal cord, and nerve networks, presenting unique diagnosis, treatment, and patient care challenges. Investment, Name [Domain] Investment, Name [Domain] Proceeds from maturities Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities Net loss per common share - basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Repurchase of the Company’s common shares Payments for Repurchase of Common Stock Total current assets Assets, Current Insider Trading Arrangements [Line Items] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Restricted cash (included in “Other assets”) Restricted Cash, Noncurrent Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments Stock Issued During Period, Value, In Connection With Equity Incentive Plans And Tax Withholding Payments The value of stock issued in connection with equity incentive plans and tax withholding payments. Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Shares Common Stock [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Genevant Sciences Ltd. Genevant Sciences Ltd. [Member] Genevant Sciences Ltd. Equity Awards Adjustments Equity Awards Adjustments [Member] Purchase obligation, to be paid, remainder of fiscal year Purchase Obligation, to be Paid, Remainder of Fiscal Year Total liabilities and shareholders’ equity Liabilities and Equity Employee Stock Option Share-Based Payment Arrangement, Option [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Other liabilities Increase (Decrease) in Other Operating Liabilities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Plan Name [Axis] Plan Name [Axis] Tabular List, Table Tabular List [Table Text Block] Vesting [Axis] Vesting [Axis] Additional paid-in capital Additional Paid in Capital Foreign currency transaction gain Foreign Currency Transaction Gain, before Tax Other expense, net Other expense, net Other Nonoperating Income (Expense) Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Address, Country Entity Address, Country Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative (includes $74,621 and $71,079 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) General and administrative expenses General and Administrative Expense Adjustment to Compensation: Adjustment to Compensation [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Class of Stock [Domain] Class of Stock [Domain] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total assets at fair value Assets, Fair Value Disclosure Investments Investment, Policy [Policy Text Block] Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Other Other Noncash Income (Expense) Other current assets Increase (Decrease) in Other Current Assets Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Debt securities, available-for-sale, unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Accrued interest receivable Interest Receivable Name Trading Arrangement, Individual Name Mosliciguat Mosliciguat [Member] Mosliciguat it is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension. Litigation settlement, number of patents Litigation Settlement, Number Of Patents Litigation Settlement, Number Of Patents Cash and cash equivalents Cash and cash equivalents Total cash and cash equivalents Cash and Cash Equivalent Research and development expenses Accrued Research And Development Expenses, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer. Company Selected Measure Amount Company Selected Measure Amount Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Entity Address, Address Line Two Entity Address, Address Line Two Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Net loss Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Entity Address, Address Line One Entity Address, Address Line One Income tax (benefit) expense Income tax (benefit) expense Income Tax Expense (Benefit) Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Purchase obligation Purchase Obligation Award Timing Method Award Timing Method [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Other research and development expenses Other Research and Development Expense Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] RSL Equity Plans Roivant Sciences Ltd Equity Plans [Member] The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "RSL 2021 EIP"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the "RSL Equity Plans"). Net loss attributable to Roivant Sciences Ltd. Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Marketable securities, held-to-maturity Marketable Securities, Held-to-Maturity [Abstract] Marketable Securities, Held-to-Maturity Restatement Determination Date: Restatement Determination Date [Axis] Proceeds from exercise of the Company’s and subsidiary stock options Proceeds from Stock Options Exercised Interest income Investment Income, Interest Foreign currency transaction losses Foreign Currency Transaction Loss, before Tax Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Other development and discovery programs Other Development And Discovery Programs [Member] Research and development expenses classified as other development and discovery programs. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]